A Phase III Double Blind Trial of Oral Duloxetine for Treatment of Pain Associated With Chemotherapy-Induced Peripheral Neuropathy.

Trial Profile

A Phase III Double Blind Trial of Oral Duloxetine for Treatment of Pain Associated With Chemotherapy-Induced Peripheral Neuropathy.

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs Duloxetine (Primary)
  • Indications Neuropathic pain
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 03 Apr 2013 Primary endpoint 'Pain-intensity' has been met.
    • 03 Apr 2013 Results published in JAMA: the Journal of the American Medical Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top